Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5
07/29/2021 - 08:30 AM
TEL AVIV, Israel , July 29, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Thursday, August 5, 2021 , to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the quarter ended June 30, 2021.
Conference Call & Webcast:
Thursday August 5, 2021 , 8:30 AM ET
Toll Free: 1-888-394-8218 Toll/International: 1-323-701-0225 Israel Toll Free: 1 809 212 883 Conference ID: 2905012 Webcast: http://public.viavid.com/index.php?id=145911
Replay Dial-In Numbers
Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 Replay Pin Number: 2905012 Replay Start: Thursday August 5, 2021, 11:30 AM ET Replay Expiry: Thursday August 19, 2021 , 11:59 PM ET
About Aramchol and Non-alcoholic Steatohepatitis (NASH)
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramchol has been granted Fast Track designation status by the FDA for the treatment of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.
View original content:https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-second-quarter-2021-financial-results-and-provide-business-update-on-thursday-august-5-301344113.html
SOURCE Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd
GLMD Rankings
N/A Ranked by Stock Gains
GLMD Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Israel
City
16 Zeev Tyomkin St 4th Fl
About GLMD
galmed pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or fabacs. aramchol is initially being developed for treating non-alcoholic steato-hepatitis, or nash, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. galmed pharmaceuticals galmed’s business has been, in its current legal structure, was incorporated in israel on july 31, 2013 as a privately held company. however, operating since 2000 under a different group of companies established in the same year. galmed was co-founded by professor tuvia gilat and allen baharaff, based on professor gilat’s extensive research in fabac’s and nash.